NCT05132582: An ongoing trial by Seagen, a wholly owned subsidiary of Pfizer
This trial is ongoing. It must report results 8 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05132582 |
|---|---|
| Title | A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 7, 2022 |
| Completion date | Sept. 5, 2025 |
| Required reporting date | Sept. 5, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |